319442-18-7 Usage
General Description
Ethyl 4-chlorothieno[3,2-d]pyrimidine-2-carboxylate, also known as simply ethyl 4-chlorothienopyrimidine-2-carboxylate, is a chemical compound that belongs to the class of thieno[3,2-d]pyrimidines. It is commonly used in the field of organic synthesis as a key building block for the preparation of various biologically active compounds and pharmaceuticals. Ethyl 4-chlorothieno[3,2-d]pyrimidine-2-carboxylate has shown potential as an anti-inflammatory and anti-cancer agent in preclinical studies. Its chemical structure and reactivity make it a valuable tool for drug discovery and development. The synthesis and characterization of ethyl 4-chlorothieno[3,2-d]pyrimidine-2-carboxylate are well-documented in the scientific literature, and it continues to be an important compound in medicinal and synthetic chemistry research.
Check Digit Verification of cas no
The CAS Registry Mumber 319442-18-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 3,1,9,4,4 and 2 respectively; the second part has 2 digits, 1 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 319442-18:
(8*3)+(7*1)+(6*9)+(5*4)+(4*4)+(3*2)+(2*1)+(1*8)=137
137 % 10 = 7
So 319442-18-7 is a valid CAS Registry Number.
InChI:InChI=1/C9H7ClN2O2S/c1-2-14-9(13)8-11-5-3-4-15-6(5)7(10)12-8/h3-4H,2H2,1H3
319442-18-7Relevant articles and documents
ALKYNYL ALCOHOLS AND METHODS OF USE
-
, (2015/03/04)
The invention relates to compounds of Formula (0): wherein A1-A8, R4 and R5 each has the meaning as described herein. Compounds of Formula (0) and pharmaceutical compositions thereof are useful in the treatment of diseases and disorders in which undesired or over-activation of NF-kB signaling is observed.
THIENOPYRIDINE AND THIENOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF
-
, (2012/03/26)
Provided herein are thienopyridine and thienopyrimidine compounds of formula (I) for treatment of JAK kinase mediated diseases, including JAK2 kinase-, JAK3 kinase- or TYK2 kinase-mediated diseases. Also provided are pharmaceutical compositions comprising